Deals
Gilead Seeks Cancer Drug Deals to Bolster 79% Share Rise: Health
This article is for subscribers only.
Gilead Sciences Inc., the world’s largest maker of HIV drugs, has spent $1.2 billion in two years to buy blood cancer drugs. It’s looking for more.
Treatment for leukemia and other blood cancers is one of the fastest growing markets for cancer drugs. Gilead’s recent string of four deals is intended to tap into that market and set the stage for the company’s growth for years.